1-(4-氯苯基)-5-甲基吡啶-2-酮 | 53427-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-(4-氯苯基)-5-甲基吡啶-2-酮
• 英文名称: 1-(4'-chlorophenyl)-5-methyl-2(1H)pyridone
• 英文别名: 1-(4'-chlorophenyl)-5-methyl-2-(1H)-pyridone；1-(4-chlorophenyl)-5-methylpyridin-2-one
• CAS: 53427-80-8
• 化学式: C₁₂H₁₀ClNO
• 分子量: 219.671
• InChiKey: KZESGAYSFUZRJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-羟基-5-甲基嘧啶 、 对氯碘苯 在 copper(l) iodide potassium phosphate 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 为溶剂， 以85%的产率得到1-(4-氯苯基)-5-甲基吡啶-2-酮
  参考文献：
  名称：

  基于布赫瓦尔德规程的吡啶-2-酮与芳基和杂环卤化物的高效铜催化偶联反应

  摘要：

  已经建立了基于布赫瓦尔德协议的高效铜催化的偶联反应，用于吡啶-2-酮与芳基碘化物，芳基溴化物和杂环溴化物。

  DOI：

  10.1016/j.tetlet.2004.04.019

文献信息

• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS
  申请人：Kossen Karl

  公开号：US20090318455A1

  公开（公告）日：2009-12-24

  Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

  公开了用于治疗炎症和纤维化疾病的化合物和方法，包括用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物对p38 MAPK的抑制效力较低；并且其中接触是在SAPK调节浓度下进行的，该浓度对化合物抑制p38 MAPK的抑制浓度百分比较低。还公开了吡非尼酮的衍生物和类似物，它们可用于调节应激活化蛋白激酶（SAPK）系统。
• PREPARATION OF 1-(SUBSTITUTED BENZYL)-5-TRIFLUOROMETHYL-2(1H)PYRIDONE COMPOUNDS AND SALTS THEREOF AND THEIR APPLICATIONS
  申请人：Hu Gaoyun

  公开号：US20120129859A1

  公开（公告）日：2012-05-24

  1-(substituted benzyl)-5-trifluoromethyl-2(1H)pyridone compounds and their pharmaceutical acceptable salts are disclosed. The preparation methods of the compounds and their salts and the use of the same for preparing the medicaments for treating fibrosis are also disclosed. New pyridine compounds and their salts are obtained from trifluoromethyl pyridone as starting material.

  揭示了1-(取代苄基)-5-三氟甲基-2(1H)吡啶酮化合物及其药用可接受盐。还公开了这些化合物及其盐的制备方法，以及用于制备治疗纤维化药物的用途。从三氟甲基吡啶酮作为起始物获得了新的吡啶化合物及其盐。
• 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use
  申请人：Affiliated Medical Research, Inc.

  公开号：US03974281A1

  公开（公告）日：1976-08-10

  Novel analgesic, anti-pyretic, anti-inflammatory compositions containing as the active ingredient the compound, 5-methyl-1-phenyl-2-(1H)-pyridone are described. Such compositions have also been found to cause significant lowering of serum uric acid and glucose levels and to be effective in the treatment of a number of upper respiratory ailments in humans and other mammals. Skin conditions such as dermatitis and poison ivy are also alleviated by this agent. The compositions containing 5-methyl-1-phenyl-2-(1H)-pyridone caused no irritation on oral administration or when applied to specific target tissues showed no significant irritation or other sequelae.

  描述了一种含有活性成分5-甲基-1-苯基-2-(1H)-吡啶酮的新型镇痛、退烧、抗炎组合物。这种组合物还被发现能显著降低血清尿酸和葡萄糖水平，并对人类和其他哺乳动物的多种上呼吸道疾病治疗有效。皮肤状况如皮炎和毒葛也可以通过这种药物缓解。含有5-甲基-1-苯基-2-(1H)-吡啶酮的组合物在口服时不引起刺激，在应用于特定靶组织时也没有显著的刺激或其他后遗症。
• MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
  申请人：BLATT LAWRENCE M.

  公开号：US20090286843A1

  公开（公告）日：2009-11-19

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合物在内的组合物。该实施例还提供了治疗方法，包括治疗黄热病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述化合物或组合物的有效量。